adenine has been researched along with Cardiovascular Diseases in 39 studies
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Medial vascular calcification is highly prevalent in chronic kidney disease (CKD), and it is a risk factor for mortality." | 5.39 | Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. ( Adams, MA; Holden, RM; Pang, J; Shobeiri, N, 2013) |
| " Given two factors associated with high mutation rates, we tested how many previously known genes match with (i) proximity to telomeres or (ii) high adenine and thymine content in cardiovascular diseases (CVDs) related to vascular stiffening." | 4.02 | Factors Associated with Mutations: Their Matching Rates to Cardiovascular and Neurological Diseases. ( Hart, C; Hijazi, A; Kim, DG; Lee, C; Lee, PHU; Li, W; Lucas, HB; McKnight, I; Raines, R; Shim, JW, 2021) |
| "DNA-based sensors can detect disease biomarkers, including acetone and ethanol for diabetes and H2S for cardiovascular diseases." | 3.83 | Ranking of Molecular Biomarker Interaction with Targeted DNA Nucleobases via Full Atomistic Molecular Dynamics. ( Cranford, SW; Wang, ML; Zhang, W, 2016) |
| " Most common adverse events (AEs) leading to prior KI discontinuation were rash (27%), arthralgia (18%), and atrial fibrillation (16%)." | 3.01 | Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. ( Barr, PM; Barrientos, JC; Brander, DM; Cheson, BD; Dorsey, C; Flinn, IW; Fonseca, GA; Ghosh, N; Hamadeh, IS; Kambhampati, S; Lamanna, N; Lansigan, F; LaRatta, N; Luning Prak, ET; Mato, AR; Miskin, HP; Pagel, JM; Paskalis, D; Pu, JJ; Rai, KR; Reeves, JA; Roeker, L; Schuster, SJ; Sitlinger, A; Skarbnik, AP; Sportelli, P; Svoboda, J; Tsao, P; Weiss, MS; Weissbrot, H, 2021) |
| "ARTEN is a randomized, open-label, non-inferiority trial that compares nevirapine (NVP) 200 mg twice daily or 400 mg once daily to atazanavir/ritonavir (ATZ/r) 300 mg/100 mg once daily, each combined with fixed-dose tenofovir disoproxil fumarate (TDF) 300 mg/emtricitabine (FTC) 200 mg once daily, in antiretroviral-naive HIV-1 patients with CD4(+) T-cell counts <400 (men) and <250 cells/mm(3) (women)." | 2.76 | Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. ( Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S, 2011) |
| " These data have now provided a clear and clinically relevant understanding of the individual profiles of drugs within the nucleoside analogue reverse transcriptase inhibitor , HIV protease inhibitor and non-nucleoside analogue reverse transcriptase inhibitor drug classes, and have provided a rational basis for assessing and monitoring these adverse effects in clinical practice." | 2.43 | Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. ( Mallal, S; Nolan, D; Reiss, P, 2005) |
| "Ibrutinib reduces mortality in chronic lymphocytic leukemia (CLL)." | 1.62 | Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study. ( Abdel-Qadir, H; Austin, PC; Calvillo-Argüelles, O; Lee, DS; Leong, D; Nanthakumar, K; Pang, A; Prica, A; Sabrie, N; Thavendiranathan, P, 2021) |
| "Medial vascular calcification is highly prevalent in chronic kidney disease (CKD), and it is a risk factor for mortality." | 1.39 | Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences. ( Adams, MA; Holden, RM; Pang, J; Shobeiri, N, 2013) |
| "Abacavir use has been associated with cardiovascular risk, but it is unknown whether this association may be partly explained by patients with kidney disease being preferentially treated with abacavir to avoid tenofovir." | 1.37 | Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. ( Choi, AI; Deeks, SG; Li, Y; Shlipak, MG; Vittinghoff, E; Weekley, CC, 2011) |
| "If abacavir or didanosine increase cardiovascular risk, it is likely not through the direct endothelial activation pathways tested in these experiments." | 1.37 | Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells. ( Clauss, M; Desta, Z; Deuter-Reinhard, M; Green, L; Gupta, SK; Kim, C; Taylor, BM, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.56) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 27 (69.23) | 24.3611 |
| 2020's | 6 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Abdel-Qadir, H | 1 |
| Sabrie, N | 1 |
| Leong, D | 1 |
| Pang, A | 1 |
| Austin, PC | 1 |
| Prica, A | 1 |
| Nanthakumar, K | 1 |
| Calvillo-Argüelles, O | 1 |
| Lee, DS | 1 |
| Thavendiranathan, P | 1 |
| Schafer, JJ | 1 |
| Zimmerman, M | 1 |
| Walshe, C | 1 |
| Cerankowski, J | 1 |
| Shimada, A | 1 |
| Keith, SW | 1 |
| Jindal, I | 1 |
| Wang, X | 5 |
| Stühlinger, MC | 1 |
| Weltermann, A | 1 |
| Staber, P | 1 |
| Heintel, D | 1 |
| Nösslinger, T | 1 |
| Steurer, M | 1 |
| Munir, T | 1 |
| Brown, JR | 2 |
| O'Brien, S | 1 |
| Barrientos, JC | 2 |
| Barr, PM | 2 |
| Reddy, NM | 2 |
| Coutre, S | 1 |
| Tam, CS | 1 |
| Mulligan, SP | 1 |
| Jaeger, U | 1 |
| Kipps, TJ | 1 |
| Moreno, C | 1 |
| Montillo, M | 1 |
| Burger, JA | 1 |
| Byrd, JC | 1 |
| Hillmen, P | 1 |
| Dai, S | 1 |
| Szoke, A | 1 |
| Dean, JP | 1 |
| Woyach, JA | 1 |
| Salem, JE | 1 |
| Manouchehri, A | 1 |
| Bretagne, M | 1 |
| Lebrun-Vignes, B | 1 |
| Groarke, JD | 1 |
| Johnson, DB | 1 |
| Yang, T | 1 |
| Funck-Brentano, C | 1 |
| Roden, DM | 1 |
| Moslehi, JJ | 1 |
| Bergler-Klein, J | 1 |
| Halim, AA | 1 |
| Alsayed, B | 1 |
| Embarak, S | 1 |
| Yaseen, T | 1 |
| Dabbous, S | 1 |
| Fontaine, O | 1 |
| Dueluzeau, R | 1 |
| Raibaud, P | 1 |
| Chabanet, C | 1 |
| Popoff, MR | 1 |
| Badoual, J | 1 |
| Gabilan, JC | 1 |
| Andremont, A | 1 |
| Gómez, L | 1 |
| Andrés, S | 1 |
| Sánchez, J | 1 |
| Alonso, JM | 1 |
| Rey, J | 1 |
| López, F | 1 |
| Jiménez, A | 1 |
| Yan, Z | 1 |
| Zhou, L | 1 |
| Zhao, Y | 3 |
| Wang, J | 6 |
| Huang, L | 2 |
| Hu, K | 1 |
| Liu, H | 4 |
| Wang, H | 3 |
| Guo, Z | 1 |
| Song, Y | 1 |
| Huang, H | 4 |
| Yang, R | 1 |
| Owen, TW | 1 |
| Al-Kaysi, RO | 1 |
| Bardeen, CJ | 1 |
| Cheng, Q | 1 |
| Wu, S | 1 |
| Cheng, T | 1 |
| Zhou, X | 1 |
| Wang, B | 4 |
| Zhang, Q | 4 |
| Wu, X | 2 |
| Yao, Y | 3 |
| Ochiai, T | 1 |
| Ishiguro, H | 2 |
| Nakano, R | 2 |
| Kubota, Y | 2 |
| Hara, M | 1 |
| Sunada, K | 1 |
| Hashimoto, K | 1 |
| Kajioka, J | 1 |
| Fujishima, A | 1 |
| Jiao, J | 3 |
| Gai, QY | 3 |
| Wang, W | 2 |
| Zang, YP | 2 |
| Niu, LL | 2 |
| Fu, YJ | 3 |
| Yao, LP | 1 |
| Qin, QP | 1 |
| Wang, ZY | 1 |
| Liu, J | 4 |
| Aleksic Sabo, V | 1 |
| Knezevic, P | 1 |
| Borges-Argáez, R | 1 |
| Chan-Balan, R | 1 |
| Cetina-Montejo, L | 1 |
| Ayora-Talavera, G | 1 |
| Sansores-Peraza, P | 1 |
| Gómez-Carballo, J | 1 |
| Cáceres-Farfán, M | 1 |
| Jang, J | 1 |
| Akin, D | 1 |
| Bashir, R | 1 |
| Yu, Z | 1 |
| Zhu, J | 2 |
| Jiang, H | 1 |
| He, C | 2 |
| Xiao, Z | 1 |
| Xu, J | 2 |
| Sun, Q | 1 |
| Han, D | 1 |
| Lei, H | 1 |
| Zhao, K | 2 |
| Zhu, L | 1 |
| Li, X | 4 |
| Fu, H | 2 |
| Wilson, BK | 1 |
| Step, DL | 1 |
| Maxwell, CL | 1 |
| Gifford, CA | 1 |
| Richards, CJ | 1 |
| Krehbiel, CR | 1 |
| Warner, JM | 1 |
| Doerr, AJ | 1 |
| Erickson, GE | 1 |
| Guretzky, JA | 1 |
| Rasby, RJ | 1 |
| Watson, AK | 1 |
| Klopfenstein, TJ | 1 |
| Sun, Y | 4 |
| Liu, Z | 3 |
| Pham, TD | 1 |
| Lee, BK | 1 |
| Yang, FC | 1 |
| Wu, KH | 1 |
| Lin, WP | 1 |
| Hu, MK | 1 |
| Lin, L | 3 |
| Shao, J | 1 |
| Sun, M | 1 |
| Xu, G | 1 |
| Zhang, X | 6 |
| Xu, N | 1 |
| Wang, R | 1 |
| Liu, S | 1 |
| He, H | 1 |
| Dong, X | 2 |
| Yang, M | 2 |
| Yang, Q | 1 |
| Duan, S | 1 |
| Yu, Y | 2 |
| Han, J | 2 |
| Zhang, C | 3 |
| Chen, L | 2 |
| Yang, X | 1 |
| Li, W | 4 |
| Wang, T | 2 |
| Campbell, DA | 1 |
| Gao, K | 1 |
| Zager, RA | 1 |
| Johnson, ACM | 1 |
| Guillem, A | 1 |
| Keyser, J | 1 |
| Singh, B | 1 |
| Steubl, D | 1 |
| Schneider, MP | 1 |
| Meiselbach, H | 1 |
| Nadal, J | 1 |
| Schmid, MC | 1 |
| Saritas, T | 1 |
| Krane, V | 1 |
| Sommerer, C | 1 |
| Baid-Agrawal, S | 1 |
| Voelkl, J | 1 |
| Kotsis, F | 1 |
| Köttgen, A | 1 |
| Eckardt, KU | 1 |
| Scherberich, JE | 1 |
| Li, H | 4 |
| Yao, L | 2 |
| Sun, L | 3 |
| Zhu, Z | 1 |
| Naren, N | 1 |
| Zhang, XX | 2 |
| Gentile, GL | 1 |
| Rupert, AS | 1 |
| Carrasco, LI | 1 |
| Garcia, EM | 1 |
| Kumar, NG | 1 |
| Walsh, SW | 1 |
| Jefferson, KK | 1 |
| Guest, RL | 1 |
| Samé Guerra, D | 1 |
| Wissler, M | 1 |
| Grimm, J | 1 |
| Silhavy, TJ | 1 |
| Lee, JH | 2 |
| Yoo, JS | 1 |
| Kim, Y | 1 |
| Kim, JS | 2 |
| Lee, EJ | 1 |
| Roe, JH | 1 |
| Delorme, M | 1 |
| Bouchard, PA | 1 |
| Simon, M | 1 |
| Simard, S | 1 |
| Lellouche, F | 1 |
| D'Urzo, KA | 1 |
| Mok, F | 1 |
| D'Urzo, AD | 1 |
| Koneru, B | 1 |
| Lopez, G | 1 |
| Farooqi, A | 1 |
| Conkrite, KL | 1 |
| Nguyen, TH | 1 |
| Macha, SJ | 1 |
| Modi, A | 1 |
| Rokita, JL | 1 |
| Urias, E | 1 |
| Hindle, A | 1 |
| Davidson, H | 1 |
| Mccoy, K | 1 |
| Nance, J | 1 |
| Yazdani, V | 1 |
| Irwin, MS | 1 |
| Yang, S | 1 |
| Wheeler, DA | 1 |
| Maris, JM | 1 |
| Diskin, SJ | 1 |
| Reynolds, CP | 1 |
| Abhilash, L | 1 |
| Kalliyil, A | 1 |
| Sheeba, V | 1 |
| Hartley, AM | 2 |
| Meunier, B | 2 |
| Pinotsis, N | 1 |
| Maréchal, A | 2 |
| Xu, JY | 1 |
| Genko, N | 1 |
| Haraux, F | 1 |
| Rich, PR | 1 |
| Kamalanathan, M | 1 |
| Doyle, SM | 1 |
| Xu, C | 1 |
| Achberger, AM | 1 |
| Wade, TL | 1 |
| Schwehr, K | 1 |
| Santschi, PH | 1 |
| Sylvan, JB | 1 |
| Quigg, A | 1 |
| Leong, W | 1 |
| Xu, W | 2 |
| Gao, S | 1 |
| Zhai, X | 1 |
| Wang, C | 2 |
| Gilson, E | 1 |
| Ye, J | 1 |
| Lu, Y | 1 |
| Yan, R | 1 |
| Zhang, Y | 6 |
| Hu, Z | 1 |
| You, Q | 1 |
| Cai, Q | 1 |
| Yang, D | 1 |
| Gu, S | 1 |
| Dai, H | 1 |
| Zhao, X | 1 |
| Gui, C | 1 |
| Gui, J | 1 |
| Wu, PK | 1 |
| Hong, SK | 1 |
| Starenki, D | 1 |
| Oshima, K | 1 |
| Shao, H | 1 |
| Gestwicki, JE | 1 |
| Tsai, S | 1 |
| Park, JI | 1 |
| Wang, Y | 7 |
| Zhao, R | 1 |
| Gu, Z | 1 |
| Dong, C | 2 |
| Guo, G | 1 |
| Li, L | 4 |
| Barrett, HE | 1 |
| Meester, EJ | 1 |
| van Gaalen, K | 1 |
| van der Heiden, K | 1 |
| Krenning, BJ | 1 |
| Beekman, FJ | 1 |
| de Blois, E | 1 |
| de Swart, J | 1 |
| Verhagen, HJ | 1 |
| Maina, T | 1 |
| Nock, BA | 1 |
| Norenberg, JP | 1 |
| de Jong, M | 1 |
| Gijsen, FJH | 1 |
| Bernsen, MR | 1 |
| Martínez-Milla, J | 1 |
| Galán-Arriola, C | 1 |
| Carnero, M | 1 |
| Cobiella, J | 1 |
| Pérez-Camargo, D | 1 |
| Bautista-Hernández, V | 1 |
| Rigol, M | 1 |
| Solanes, N | 1 |
| Villena-Gutierrez, R | 1 |
| Lobo, M | 1 |
| Mateo, J | 1 |
| Vilchez-Tschischke, JP | 1 |
| Salinas, B | 1 |
| Cussó, L | 1 |
| López, GJ | 1 |
| Fuster, V | 1 |
| Desco, M | 1 |
| Sanchez-González, J | 1 |
| Ibanez, B | 1 |
| van den Berg, P | 1 |
| Schweitzer, DH | 1 |
| van Haard, PMM | 1 |
| Geusens, PP | 1 |
| van den Bergh, JP | 1 |
| Zhu, X | 1 |
| Huang, X | 2 |
| Xu, H | 2 |
| Yang, G | 2 |
| Lin, Z | 1 |
| Salem, HF | 1 |
| Nafady, MM | 1 |
| Kharshoum, RM | 1 |
| Abd El-Ghafar, OA | 1 |
| Farouk, HO | 1 |
| Domiciano, D | 1 |
| Nery, FC | 1 |
| de Carvalho, PA | 1 |
| Prudente, DO | 1 |
| de Souza, LB | 1 |
| Chalfun-Júnior, A | 1 |
| Paiva, R | 1 |
| Marchiori, PER | 1 |
| Lu, M | 2 |
| An, Z | 1 |
| Jiang, J | 2 |
| Li, J | 7 |
| Du, S | 1 |
| Zhou, H | 1 |
| Cui, J | 1 |
| Wu, W | 1 |
| Liu, Y | 7 |
| Song, J | 1 |
| Lian, Q | 1 |
| Uddin Ahmad, Z | 1 |
| Gang, DD | 1 |
| Konggidinata, MI | 1 |
| Gallo, AA | 1 |
| Zappi, ME | 1 |
| Yang, TWW | 1 |
| Johari, Y | 1 |
| Burton, PR | 1 |
| Earnest, A | 1 |
| Shaw, K | 1 |
| Hare, JL | 1 |
| Brown, WA | 1 |
| Kim, GA | 1 |
| Han, S | 1 |
| Choi, GH | 1 |
| Choi, J | 1 |
| Lim, YS | 1 |
| Gallo, A | 1 |
| Cancelli, C | 1 |
| Ceron, E | 1 |
| Covino, M | 1 |
| Capoluongo, E | 1 |
| Pocino, K | 1 |
| Ianiro, G | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 1 |
| Montalto, M | 1 |
| Somasundar, Y | 1 |
| Lu, IC | 1 |
| Mills, MR | 1 |
| Qian, LY | 1 |
| Olivares, X | 1 |
| Ryabov, AD | 1 |
| Collins, TJ | 1 |
| Zhao, L | 1 |
| Doddipatla, S | 1 |
| Thomas, AM | 1 |
| Nikolayev, AA | 1 |
| Galimova, GR | 1 |
| Azyazov, VN | 1 |
| Mebel, AM | 1 |
| Kaiser, RI | 1 |
| Guo, S | 1 |
| Yang, P | 1 |
| Yu, X | 2 |
| Wu, Y | 2 |
| Zhang, H | 1 |
| Yu, B | 2 |
| Han, B | 1 |
| George, MW | 1 |
| Moor, MB | 1 |
| Bonny, O | 1 |
| Langenberg, E | 1 |
| Paik, H | 1 |
| Smith, EH | 1 |
| Nair, HP | 1 |
| Hanke, I | 1 |
| Ganschow, S | 1 |
| Catalan, G | 1 |
| Domingo, N | 1 |
| Schlom, DG | 1 |
| Assefa, MK | 1 |
| Wu, G | 2 |
| Hayton, TW | 1 |
| Becker, B | 1 |
| Enikeev, D | 1 |
| Netsch, C | 1 |
| Gross, AJ | 1 |
| Laukhtina, E | 1 |
| Glybochko, P | 1 |
| Rapoport, L | 1 |
| Herrmann, TRW | 1 |
| Taratkin, M | 1 |
| Dai, W | 1 |
| Shi, J | 2 |
| Carreno, J | 1 |
| Kloner, RA | 1 |
| Pickersgill, NA | 1 |
| Vetter, JM | 1 |
| Kim, EH | 1 |
| Cope, SJ | 1 |
| Du, K | 1 |
| Venkatesh, R | 1 |
| Giardina, JD | 1 |
| Saad, NES | 1 |
| Bhayani, SB | 1 |
| Figenshau, RS | 1 |
| Eriksson, J | 1 |
| Landfeldt, E | 1 |
| Ireland, S | 1 |
| Jackson, C | 1 |
| Wyatt, E | 1 |
| Gaudig, M | 1 |
| Stancill, JS | 1 |
| Happ, JT | 1 |
| Broniowska, KA | 1 |
| Hogg, N | 1 |
| Corbett, JA | 1 |
| Tang, LF | 1 |
| Bi, YL | 1 |
| Fan, Y | 2 |
| Sun, YB | 1 |
| Wang, AL | 1 |
| Xiao, BH | 1 |
| Wang, LF | 1 |
| Qiu, SW | 1 |
| Guo, SW | 1 |
| Wáng, YXJ | 1 |
| Sun, J | 2 |
| Chu, S | 1 |
| Pan, Q | 1 |
| Li, D | 2 |
| Zheng, S | 2 |
| Ma, L | 1 |
| Wang, L | 3 |
| Hu, T | 1 |
| Wang, F | 1 |
| Han, Z | 1 |
| Yin, Z | 1 |
| Ge, X | 1 |
| Xie, K | 1 |
| Lei, P | 1 |
| Dias-Santagata, D | 1 |
| Lennerz, JK | 1 |
| Sadow, PM | 1 |
| Frazier, RP | 1 |
| Govinda Raju, S | 1 |
| Henry, D | 1 |
| Chung, T | 1 |
| Kherani, J | 1 |
| Rothenberg, SM | 1 |
| Wirth, LJ | 1 |
| Marti, CN | 1 |
| Choi, NG | 1 |
| Bae, SJ | 1 |
| Ni, L | 1 |
| Luo, X | 1 |
| Dai, T | 1 |
| Yang, Y | 3 |
| Lee, R | 1 |
| Fleischer, AS | 1 |
| Wemhoff, AP | 1 |
| Ford, CR | 1 |
| Kleppinger, EL | 1 |
| Helms, K | 1 |
| Bush, AA | 1 |
| Luna-Abanto, J | 1 |
| García Ruiz, L | 1 |
| Laura Martinez, J | 1 |
| Álvarez Larraondo, M | 1 |
| Villoslada Terrones, V | 1 |
| Dukic, L | 1 |
| Maric, N | 1 |
| Simundic, AM | 1 |
| Chogtu, B | 1 |
| Ommurugan, B | 1 |
| Thomson, SR | 1 |
| Kalthur, SG | 1 |
| Benidir, M | 1 |
| El Massoudi, S | 1 |
| El Ghadraoui, L | 1 |
| Lazraq, A | 1 |
| Benjelloun, M | 1 |
| Errachidi, F | 1 |
| Cassar, M | 1 |
| Law, AD | 1 |
| Chow, ES | 1 |
| Giebultowicz, JM | 1 |
| Kretzschmar, D | 1 |
| Salonurmi, T | 1 |
| Nabil, H | 1 |
| Ronkainen, J | 1 |
| Hyötyläinen, T | 1 |
| Hautajärvi, H | 1 |
| Savolainen, MJ | 1 |
| Tolonen, A | 1 |
| Orešič, M | 1 |
| Känsäkoski, P | 1 |
| Rysä, J | 1 |
| Hakkola, J | 1 |
| Hukkanen, J | 1 |
| Zhu, N | 1 |
| Li, Y | 5 |
| Du, Q | 1 |
| Hao, P | 1 |
| Cao, X | 1 |
| Li, CX | 1 |
| Zhao, S | 1 |
| Luo, XM | 1 |
| Feng, JX | 1 |
| Gonzalez-Cotto, M | 1 |
| Guo, L | 1 |
| Karwan, M | 1 |
| Sen, SK | 1 |
| Barb, J | 1 |
| Collado, CJ | 1 |
| Elloumi, F | 1 |
| Palmieri, EM | 1 |
| Boelte, K | 1 |
| Kolodgie, FD | 1 |
| Finn, AV | 1 |
| Biesecker, LG | 1 |
| McVicar, DW | 1 |
| Qu, F | 1 |
| Deng, Z | 1 |
| Xie, Y | 2 |
| Tang, J | 3 |
| Chen, Z | 2 |
| Luo, W | 1 |
| Xiong, D | 1 |
| Zhao, D | 1 |
| Fang, J | 1 |
| Zhou, Z | 1 |
| Niu, PP | 1 |
| Song, B | 1 |
| Xu, YM | 1 |
| Zhang, Z | 2 |
| Qiu, N | 1 |
| Yin, J | 1 |
| Zhang, J | 3 |
| Guo, W | 1 |
| Liu, M | 2 |
| Liu, T | 2 |
| Chen, D | 5 |
| Luo, K | 1 |
| He, Z | 2 |
| Zheng, G | 1 |
| Xu, F | 1 |
| Sun, W | 1 |
| Yin, F | 1 |
| van Hest, JCM | 1 |
| Du, L | 2 |
| Shi, X | 1 |
| Kang, S | 1 |
| Duan, W | 1 |
| Zhang, S | 2 |
| Feng, J | 2 |
| Qi, N | 1 |
| Shen, G | 1 |
| Ren, H | 1 |
| Shang, Q | 1 |
| Zhao, W | 2 |
| Yang, Z | 2 |
| Jiang, X | 2 |
| Alame, M | 1 |
| Cornillot, E | 1 |
| Cacheux, V | 1 |
| Tosato, G | 1 |
| Four, M | 1 |
| De Oliveira, L | 1 |
| Gofflot, S | 1 |
| Delvenne, P | 1 |
| Turtoi, E | 1 |
| Cabello-Aguilar, S | 1 |
| Nishiyama, M | 1 |
| Turtoi, A | 1 |
| Costes-Martineau, V | 1 |
| Colinge, J | 1 |
| Guo, Q | 1 |
| Quan, M | 1 |
| Dong, J | 1 |
| Bai, J | 1 |
| Han, R | 1 |
| Cai, Y | 1 |
| Lv, YQ | 1 |
| Chen, Q | 1 |
| Lyu, HD | 1 |
| Deng, L | 1 |
| Zhou, D | 1 |
| Xiao, X | 1 |
| De Langhe, S | 1 |
| Billadeau, DD | 1 |
| Lou, Z | 1 |
| Zhang, JS | 1 |
| Xue, Z | 1 |
| Shen, XD | 1 |
| Gao, F | 1 |
| Busuttil, RW | 1 |
| Kupiec-Weglinski, JW | 1 |
| Ji, H | 1 |
| Otano, I | 1 |
| Alvarez, M | 1 |
| Minute, L | 1 |
| Ochoa, MC | 1 |
| Migueliz, I | 1 |
| Molina, C | 1 |
| Azpilikueta, A | 1 |
| de Andrea, CE | 1 |
| Etxeberria, I | 1 |
| Sanmamed, MF | 1 |
| Teijeira, Á | 1 |
| Berraondo, P | 1 |
| Melero, I | 1 |
| Zhong, Z | 1 |
| Xie, X | 1 |
| Yu, Q | 1 |
| Zhou, C | 1 |
| Liu, C | 2 |
| Liu, W | 1 |
| Chen, W | 1 |
| Yin, Y | 1 |
| Li, CW | 1 |
| Hsu, JL | 1 |
| Zhou, Q | 1 |
| Hu, B | 1 |
| Fu, P | 1 |
| Atyah, M | 1 |
| Ma, Q | 2 |
| Xu, Y | 1 |
| Dong, Q | 1 |
| Hung, MC | 1 |
| Ren, N | 1 |
| Huang, P | 1 |
| Liao, R | 1 |
| Chen, X | 3 |
| Cao, Q | 1 |
| Yuan, X | 1 |
| Nie, W | 1 |
| Yang, J | 2 |
| Shao, B | 1 |
| Ma, X | 1 |
| Bi, Z | 1 |
| Liang, X | 1 |
| Tie, Y | 1 |
| Mo, F | 1 |
| Xie, D | 1 |
| Wei, Y | 1 |
| Wei, X | 2 |
| Dokla, EME | 1 |
| Fang, CS | 1 |
| Chu, PC | 1 |
| Chang, CS | 1 |
| Abouzid, KAM | 1 |
| Chen, CS | 1 |
| Blaszczyk, R | 1 |
| Brzezinska, J | 1 |
| Dymek, B | 1 |
| Stanczak, PS | 1 |
| Mazurkiewicz, M | 1 |
| Olczak, J | 1 |
| Nowicka, J | 1 |
| Dzwonek, K | 1 |
| Zagozdzon, A | 1 |
| Golab, J | 1 |
| Golebiowski, A | 1 |
| Xin, Z | 1 |
| Himmelbauer, MK | 1 |
| Jones, JH | 1 |
| Enyedy, I | 1 |
| Gilfillan, R | 1 |
| Hesson, T | 1 |
| King, K | 1 |
| Marcotte, DJ | 1 |
| Murugan, P | 1 |
| Santoro, JC | 1 |
| Gonzalez-Lopez de Turiso, F | 1 |
| Pedron, J | 1 |
| Boudot, C | 1 |
| Brossas, JY | 1 |
| Pinault, E | 1 |
| Bourgeade-Delmas, S | 1 |
| Sournia-Saquet, A | 1 |
| Boutet-Robinet, E | 1 |
| Destere, A | 1 |
| Tronnet, A | 1 |
| Bergé, J | 1 |
| Bonduelle, C | 1 |
| Deraeve, C | 1 |
| Pratviel, G | 1 |
| Stigliani, JL | 1 |
| Paris, L | 1 |
| Mazier, D | 1 |
| Corvaisier, S | 1 |
| Since, M | 1 |
| Malzert-Fréon, A | 1 |
| Wyllie, S | 1 |
| Milne, R | 1 |
| Fairlamb, AH | 1 |
| Valentin, A | 1 |
| Courtioux, B | 1 |
| Verhaeghe, P | 1 |
| Fang, X | 1 |
| Gao, M | 1 |
| Gao, H | 1 |
| Bi, W | 1 |
| Tang, H | 1 |
| Cui, Y | 1 |
| Zhang, L | 3 |
| Fan, H | 1 |
| Yu, H | 1 |
| Mathison, CJN | 1 |
| Chianelli, D | 1 |
| Rucker, PV | 1 |
| Nelson, J | 1 |
| Roland, J | 1 |
| Huang, Z | 2 |
| Xie, YF | 1 |
| Epple, R | 1 |
| Bursulaya, B | 1 |
| Lee, C | 2 |
| Gao, MY | 1 |
| Shaffer, J | 1 |
| Briones, S | 1 |
| Sarkisova, Y | 1 |
| Galkin, A | 1 |
| Li, N | 1 |
| Li, C | 2 |
| Hua, S | 1 |
| Kasibhatla, S | 1 |
| Kinyamu-Akunda, J | 1 |
| Kikkawa, R | 1 |
| Molteni, V | 1 |
| Tellew, JE | 1 |
| Jin, X | 1 |
| Pang, B | 1 |
| Liu, Q | 2 |
| Liu, X | 3 |
| Huang, Y | 2 |
| Josephine Fauci, A | 1 |
| Ma, Y | 1 |
| Soo Lee, M | 1 |
| Yuan, W | 1 |
| Gao, R | 1 |
| Qi, H | 1 |
| Zheng, W | 1 |
| Yang, F | 2 |
| Chua, H | 1 |
| Wang, K | 1 |
| Ou, Y | 1 |
| Huang, M | 1 |
| Zhu, Y | 1 |
| Yu, J | 1 |
| Tian, J | 1 |
| Zhao, M | 1 |
| Hu, J | 1 |
| Yao, C | 1 |
| Zhang, B | 1 |
| Usawachintachit, M | 1 |
| Tzou, DT | 1 |
| Washington, SL | 1 |
| Hu, W | 1 |
| Chi, T | 1 |
| Sorensen, MD | 1 |
| Bailey, MR | 1 |
| Hsi, RS | 1 |
| Cunitz, BW | 1 |
| Simon, J | 1 |
| Wang, YN | 1 |
| Dunmire, BL | 1 |
| Paun, M | 1 |
| Starr, F | 1 |
| Lu, W | 1 |
| Evan, AP | 1 |
| Harper, JD | 1 |
| Han, G | 1 |
| Rodrigues, AE | 1 |
| Fouladvand, F | 1 |
| Falahi, E | 1 |
| Asbaghi, O | 1 |
| Abbasnezhad, A | 1 |
| Anigboro, AA | 1 |
| Avwioroko, OJ | 1 |
| Cholu, CO | 1 |
| Sonei, A | 1 |
| Fazelipour, S | 1 |
| Kanaani, L | 1 |
| Jahromy, MH | 1 |
| Jo, K | 1 |
| Hong, KB | 1 |
| Suh, HJ | 1 |
| Park, JH | 1 |
| Shin, E | 1 |
| Park, E | 1 |
| Kouakou-Kouamé, CA | 1 |
| N'guessan, FK | 1 |
| Montet, D | 1 |
| Djè, MK | 1 |
| Kim, GD | 1 |
| González-Fernández, D | 1 |
| Pons, EDC | 1 |
| Rueda, D | 1 |
| Sinisterra, OT | 1 |
| Murillo, E | 1 |
| Scott, ME | 1 |
| Koski, KG | 1 |
| Shete, PB | 1 |
| Gonzales, R | 1 |
| Ackerman, S | 1 |
| Cattamanchi, A | 1 |
| Handley, MA | 1 |
| Li, XX | 1 |
| Xiao, SZ | 1 |
| Gu, FF | 1 |
| He, WP | 1 |
| Ni, YX | 1 |
| Han, LZ | 1 |
| Heffernan, JK | 1 |
| Valgepea, K | 1 |
| de Souza Pinto Lemgruber, R | 1 |
| Casini, I | 1 |
| Plan, M | 1 |
| Tappel, R | 1 |
| Simpson, SD | 1 |
| Köpke, M | 1 |
| Nielsen, LK | 1 |
| Marcellin, E | 1 |
| Cen, YK | 1 |
| Lin, JG | 1 |
| Wang, YL | 1 |
| Wang, JY | 1 |
| Liu, ZQ | 1 |
| Zheng, YG | 1 |
| Spirk, D | 1 |
| Noll, S | 1 |
| Burnier, M | 1 |
| Rimoldi, S | 1 |
| Noll, G | 1 |
| Sudano, I | 1 |
| Penzhorn, BL | 1 |
| Oosthuizen, MC | 1 |
| Kobos, LM | 1 |
| Alqatani, S | 1 |
| Ferreira, CR | 1 |
| Aryal, UK | 1 |
| Hedrick, V | 1 |
| Sobreira, TJP | 1 |
| Shannahan, JH | 1 |
| Gale, P | 1 |
| Singhroy, DN | 1 |
| MacLean, E | 1 |
| Kohli, M | 1 |
| Lessem, E | 1 |
| Branigan, D | 1 |
| England, K | 1 |
| Suleiman, K | 1 |
| Drain, PK | 1 |
| Ruhwald, M | 1 |
| Schumacher, S | 1 |
| Denkinger, CM | 1 |
| Waning, B | 1 |
| Van Gemert, W | 1 |
| Pai, M | 1 |
| Myers, RK | 1 |
| Bonsu, JM | 1 |
| Carey, ME | 1 |
| Yerys, BE | 1 |
| Mollen, CJ | 1 |
| Curry, AE | 1 |
| Douglas, TA | 1 |
| Alinezhadbalalami, N | 1 |
| Balani, N | 1 |
| Schmelz, EM | 1 |
| Davalos, RV | 1 |
| Kamaldinov, T | 1 |
| Erndt-Marino, J | 1 |
| Levin, M | 1 |
| Kaplan, DL | 1 |
| Hahn, MS | 1 |
| Heidarimoghadam, R | 1 |
| Farmany, A | 1 |
| Lee, JJ | 1 |
| Kang, J | 1 |
| Park, S | 1 |
| Cho, JH | 1 |
| Oh, S | 1 |
| Park, DJ | 1 |
| Perez-Maldonado, R | 1 |
| Cho, JY | 1 |
| Park, IH | 1 |
| Kim, HB | 1 |
| Song, M | 1 |
| Mfarrej, B | 1 |
| Jofra, T | 1 |
| Morsiani, C | 1 |
| Gagliani, N | 1 |
| Fousteri, G | 1 |
| Battaglia, M | 1 |
| Giuliano, C | 1 |
| Levinger, I | 1 |
| Vogrin, S | 1 |
| Neil, CJ | 1 |
| Allen, JD | 1 |
| Lv, Y | 1 |
| Yuan, R | 1 |
| Cai, B | 1 |
| Bahrami, B | 1 |
| Chowdhury, AH | 1 |
| Yang, C | 2 |
| Qiao, Q | 1 |
| Liu, SF | 1 |
| Zhang, WH | 1 |
| Kolano, L | 1 |
| Knappe, D | 1 |
| Volke, D | 1 |
| Sträter, N | 1 |
| Hoffmann, R | 1 |
| Coussens, M | 1 |
| Calders, P | 1 |
| Lapauw, B | 1 |
| Celie, B | 1 |
| Banica, T | 1 |
| De Wandele, I | 1 |
| Pacey, V | 1 |
| Malfait, F | 1 |
| Rombaut, L | 1 |
| Vieira, D | 1 |
| Angel, S | 1 |
| Honjol, Y | 1 |
| Gruenheid, S | 1 |
| Gbureck, U | 1 |
| Harvey, E | 1 |
| Merle, G | 1 |
| Seo, G | 1 |
| Lee, G | 1 |
| Kim, MJ | 1 |
| Baek, SH | 1 |
| Choi, M | 1 |
| Ku, KB | 1 |
| Lee, CS | 1 |
| Jun, S | 1 |
| Park, D | 1 |
| Kim, HG | 1 |
| Kim, SJ | 1 |
| Lee, JO | 1 |
| Kim, BT | 1 |
| Park, EC | 1 |
| Kim, SI | 1 |
| Ende, M | 1 |
| Kirkkala, T | 1 |
| Loitzenbauer, M | 1 |
| Talla, D | 1 |
| Wildner, M | 1 |
| Miletich, R | 1 |
| Criado, A | 1 |
| Lavela, P | 1 |
| Tirado, JL | 1 |
| Pérez-Vicente, C | 1 |
| Kang, D | 1 |
| Feng, D | 2 |
| Fang, Z | 1 |
| Wei, F | 1 |
| De Clercq, E | 1 |
| Pannecouque, C | 1 |
| Zhan, P | 1 |
| Guo, Y | 1 |
| Shen, Y | 1 |
| Wang, Q | 2 |
| Kawazoe, Y | 1 |
| Jena, P | 1 |
| Sun, Z | 1 |
| Li, Z | 2 |
| Liang, H | 1 |
| Xu, X | 1 |
| Ma, G | 1 |
| Huo, X | 1 |
| Church, JS | 1 |
| Chace-Donahue, F | 1 |
| Blum, JL | 1 |
| Ratner, JR | 1 |
| Zelikoff, JT | 1 |
| Schwartzer, JJ | 1 |
| Fiseha, T | 1 |
| Tamir, Z | 1 |
| Yao, W | 1 |
| Wang, P | 1 |
| Mi, K | 1 |
| Cheng, J | 1 |
| Gu, C | 1 |
| Huang, J | 2 |
| Sun, HB | 1 |
| Xing, WQ | 1 |
| Liu, XB | 1 |
| Zheng, Y | 1 |
| Yang, SJ | 1 |
| Wang, ZF | 1 |
| Liu, SL | 1 |
| Ba, YF | 1 |
| Zhang, RX | 1 |
| Liu, BX | 1 |
| Fan, CC | 1 |
| Chen, PN | 1 |
| Liang, GH | 1 |
| Yu, YK | 1 |
| Wang, HR | 1 |
| Li, HM | 1 |
| Li, ZX | 1 |
| Lalani, SS | 1 |
| Anasir, MI | 1 |
| Poh, CL | 1 |
| Khan, IT | 1 |
| Nadeem, M | 1 |
| Imran, M | 1 |
| Khalique, A | 1 |
| Raspini, B | 1 |
| Porri, D | 1 |
| De Giuseppe, R | 1 |
| Chieppa, M | 1 |
| Liso, M | 1 |
| Cerbo, RM | 1 |
| Civardi, E | 1 |
| Garofoli, F | 1 |
| Monti, MC | 1 |
| Vacca, M | 1 |
| De Angelis, M | 1 |
| Cena, H | 1 |
| Kong, D | 1 |
| Han, X | 1 |
| Zhou, Y | 3 |
| Xue, H | 1 |
| Zhang, W | 2 |
| Ruan, Z | 1 |
| Li, S | 2 |
| Noer, PR | 1 |
| Kjaer-Sorensen, K | 1 |
| Juhl, AK | 1 |
| Goldstein, A | 1 |
| Ke, C | 1 |
| Oxvig, C | 1 |
| Duan, C | 1 |
| Kong, F | 1 |
| Lin, S | 1 |
| Wang, Z | 2 |
| Bhattacharya, R | 1 |
| Mazumder, D | 1 |
| Yan, X | 1 |
| Ma, C | 1 |
| Tang, Y | 1 |
| Kong, X | 1 |
| Lu, J | 1 |
| Zhang, M | 1 |
| Vital-Jacome, M | 1 |
| Cazares-Granillo, M | 1 |
| Carrillo-Reyes, J | 1 |
| Buitron, G | 1 |
| Jacob, SI | 1 |
| Douair, I | 1 |
| Maron, L | 1 |
| Ménard, G | 1 |
| Rusjan, P | 1 |
| Sabioni, P | 1 |
| Di Ciano, P | 1 |
| Mansouri, E | 1 |
| Boileau, I | 1 |
| Laveillé, A | 1 |
| Capet, M | 1 |
| Duvauchelle, T | 1 |
| Schwartz, JC | 1 |
| Robert, P | 1 |
| Le Foll, B | 1 |
| Xia, Y | 1 |
| Chen, S | 1 |
| Luo, M | 1 |
| Wu, J | 1 |
| Cai, S | 1 |
| He, Y | 2 |
| Garbacz, P | 1 |
| Misiak, M | 1 |
| Jackowski, K | 1 |
| Yuan, Q | 1 |
| Sherrell, PC | 1 |
| Chen, J | 2 |
| Bi, X | 1 |
| Nutho, B | 1 |
| Mahalapbutr, P | 1 |
| Hengphasatporn, K | 1 |
| Pattaranggoon, NC | 1 |
| Simanon, N | 1 |
| Shigeta, Y | 1 |
| Hannongbua, S | 1 |
| Rungrotmongkol, T | 1 |
| Caffrey, PJ | 1 |
| Kher, R | 1 |
| Bian, K | 1 |
| Delaney, S | 1 |
| Xue, J | 1 |
| Wu, P | 1 |
| Xu, L | 1 |
| Yuan, Y | 1 |
| Luo, J | 1 |
| Ye, S | 1 |
| Ustriyana, P | 1 |
| Wei, B | 1 |
| Raee, E | 1 |
| Hu, Y | 1 |
| Wesdemiotis, C | 1 |
| Sahai, N | 1 |
| Kaur, A | 1 |
| Nigam, K | 1 |
| Srivastava, S | 1 |
| Tyagi, A | 1 |
| Dang, S | 1 |
| Millar, JE | 1 |
| Bartnikowski, N | 1 |
| Passmore, MR | 1 |
| Obonyo, NG | 1 |
| Malfertheiner, MV | 1 |
| von Bahr, V | 1 |
| Redd, MA | 1 |
| See Hoe, L | 1 |
| Ki, KK | 1 |
| Pedersen, S | 1 |
| Boyle, AJ | 1 |
| Baillie, JK | 1 |
| Shekar, K | 1 |
| Palpant, N | 1 |
| Suen, JY | 1 |
| Matthay, MA | 1 |
| McAuley, DF | 1 |
| Fraser, JF | 1 |
| Settles, JA | 1 |
| Gerety, GF | 1 |
| Spaepen, E | 1 |
| Suico, JG | 1 |
| Child, CJ | 1 |
| Oh, BL | 1 |
| Lee, JS | 1 |
| Lee, EY | 1 |
| Lee, HY | 1 |
| Yu, HG | 1 |
| Leslie, I | 1 |
| Boos, LA | 1 |
| Larkin, J | 1 |
| Pickering, L | 1 |
| Lima, HK | 1 |
| Vogel, K | 1 |
| Hampel, D | 1 |
| Wagner-Gillespie, M | 1 |
| Fogleman, AD | 1 |
| Ferraz, SL | 1 |
| O'Connor, M | 1 |
| Mazzucchelli, TG | 1 |
| Kajiyama, H | 1 |
| Suzuki, S | 1 |
| Shimbo, A | 1 |
| Utsumi, F | 1 |
| Yoshikawa, N | 1 |
| Kikkawa, F | 1 |
| Javvaji, PK | 1 |
| Dhali, A | 1 |
| Francis, JR | 1 |
| Kolte, AP | 1 |
| Roy, SC | 1 |
| Selvaraju, S | 1 |
| Mech, A | 1 |
| Sejian, V | 1 |
| DeSilva, S | 1 |
| Vaidya, SS | 1 |
| Mao, C | 1 |
| Akhatayeva, Z | 1 |
| Cheng, H | 1 |
| Zhang, G | 1 |
| Jiang, F | 1 |
| Meng, X | 1 |
| Elnour, IE | 1 |
| Lan, X | 1 |
| Song, E | 1 |
| Rohde, S | 1 |
| Antonides, CFJ | 1 |
| Muslem, R | 1 |
| de Woestijne, PCV | 1 |
| der Meulen, MHV | 1 |
| Kraemer, US | 1 |
| Dalinghaus, M | 1 |
| Bogers, AJJC | 1 |
| Pourmand, A | 1 |
| Ghassemi, M | 1 |
| Sumon, K | 1 |
| Amini, SB | 1 |
| Hood, C | 1 |
| Sikka, N | 1 |
| Duan, H | 1 |
| Chen, WP | 1 |
| Fan, M | 1 |
| Wang, WP | 1 |
| Yu, L | 1 |
| Tan, SJ | 1 |
| Xin, S | 1 |
| Wan, LJ | 1 |
| Guo, YG | 1 |
| Tanda, S | 1 |
| Gingl, K | 1 |
| Ličbinský, R | 1 |
| Hegrová, J | 1 |
| Goessler, W | 1 |
| Li, ZL | 1 |
| Zhou, YL | 1 |
| Yan, W | 1 |
| Luo, L | 1 |
| Su, ZZ | 1 |
| Fan, MZ | 1 |
| Wang, SR | 1 |
| Zhao, WG | 1 |
| Xu, D | 1 |
| Hassan, HM | 1 |
| Jiang, Z | 1 |
| Bachmann, KF | 1 |
| Haenggi, M | 1 |
| Jakob, SM | 1 |
| Takala, J | 1 |
| Gattinoni, L | 1 |
| Berger, D | 1 |
| Bentley, RF | 1 |
| Vecchiarelli, E | 1 |
| Banks, L | 1 |
| Gonçalves, PEO | 1 |
| Thomas, SG | 1 |
| Goodman, JM | 1 |
| Mather, K | 1 |
| Boachie, R | 1 |
| Anini, Y | 1 |
| Panahi, S | 1 |
| Anderson, GH | 1 |
| Luhovyy, BL | 1 |
| Nafie, MS | 1 |
| Arafa, K | 1 |
| Sedky, NK | 1 |
| Alakhdar, AA | 1 |
| Arafa, RK | 1 |
| Fan, S | 1 |
| Hu, H | 1 |
| Liang, J | 1 |
| Hu, BC | 1 |
| Wen, Z | 1 |
| Hu, D | 1 |
| Liu, YY | 1 |
| Chu, Q | 1 |
| Wu, MC | 1 |
| Lu, X | 1 |
| Wang, D | 1 |
| Hu, M | 1 |
| Shen, H | 1 |
| Yao, M | 1 |
| Dahlgren, RA | 1 |
| Vysloužil, J | 1 |
| Kulich, P | 1 |
| Zeman, T | 1 |
| Vaculovič, T | 1 |
| Tvrdoňová, M | 1 |
| Mikuška, P | 1 |
| Večeřa, Z | 1 |
| Stráská, J | 1 |
| Moravec, P | 1 |
| Balcar, VJ | 1 |
| Šerý, O | 1 |
| Qiao, L | 1 |
| Xiong, X | 1 |
| Peng, X | 1 |
| Zheng, J | 1 |
| Duan, J | 1 |
| Xiao, W | 1 |
| Zhou, HY | 1 |
| Sui, ZY | 1 |
| Zhao, FL | 1 |
| Sun, YN | 1 |
| Wang, HY | 1 |
| Han, BH | 1 |
| Jintao, X | 1 |
| Shasha, Y | 1 |
| Jincai, W | 1 |
| Chunyan, L | 1 |
| Mengya, Y | 1 |
| Yongli, S | 1 |
| Rasoanirina, BNV | 1 |
| Lassoued, MA | 1 |
| Miladi, K | 1 |
| Razafindrakoto, Z | 1 |
| Chaâbane-Banaoues, R | 1 |
| Ramanitrahasimbola, D | 1 |
| Cornet, M | 1 |
| Sfar, S | 1 |
| Liang, C | 1 |
| Xing, Q | 1 |
| Yi, JL | 1 |
| Zhang, YQ | 1 |
| Li, CY | 1 |
| Tang, SJ | 1 |
| Gao, C | 1 |
| Sun, X | 1 |
| Peng, M | 1 |
| Sun, XF | 1 |
| Zhang, T | 1 |
| Shi, JH | 1 |
| Liao, CX | 1 |
| Gao, WJ | 1 |
| Sun, LL | 1 |
| Gao, Y | 1 |
| Cao, WH | 1 |
| Lyu, J | 1 |
| Yu, CQ | 1 |
| Wang, SF | 1 |
| Pang, ZC | 1 |
| Cong, LM | 1 |
| Dong, Z | 1 |
| Wu, F | 1 |
| Wu, XP | 1 |
| Jiang, GH | 1 |
| Wang, XJ | 1 |
| Wang, BY | 1 |
| Li, LM | 1 |
| Pan, L | 1 |
| Wan, SP | 1 |
| Yi, HWL | 1 |
| He, HJ | 1 |
| Yong, ZP | 1 |
| Shan, GL | 1 |
| Weng, TT | 1 |
| Yan, SQ | 1 |
| Gao, GP | 1 |
| Wei, C | 1 |
| Tao, FB | 1 |
| Shao, ZH | 1 |
| Yao, T | 1 |
| Dong, S | 1 |
| Shi, S | 1 |
| Feng, YL | 1 |
| Zhang, YW | 1 |
| Wang, SP | 1 |
| Shi, AX | 1 |
| Operario, D | 1 |
| Zhang, ZH | 1 |
| Zhu, XF | 1 |
| Zaller, N | 1 |
| Gao, P | 1 |
| Sun, YH | 1 |
| Zhang, HB | 1 |
| Mato, AR | 1 |
| Ghosh, N | 1 |
| Schuster, SJ | 1 |
| Lamanna, N | 1 |
| Pagel, JM | 1 |
| Flinn, IW | 1 |
| Rai, KR | 1 |
| Reeves, JA | 1 |
| Cheson, BD | 1 |
| Kambhampati, S | 1 |
| Lansigan, F | 1 |
| Pu, JJ | 1 |
| Skarbnik, AP | 1 |
| Roeker, L | 1 |
| Fonseca, GA | 1 |
| Sitlinger, A | 1 |
| Hamadeh, IS | 1 |
| Dorsey, C | 1 |
| LaRatta, N | 1 |
| Weissbrot, H | 1 |
| Luning Prak, ET | 1 |
| Tsao, P | 1 |
| Paskalis, D | 1 |
| Sportelli, P | 1 |
| Miskin, HP | 1 |
| Weiss, MS | 1 |
| Svoboda, J | 1 |
| Brander, DM | 1 |
| Lucas, HB | 1 |
| McKnight, I | 1 |
| Raines, R | 1 |
| Hijazi, A | 1 |
| Hart, C | 1 |
| Kim, DG | 1 |
| Lee, PHU | 1 |
| Shim, JW | 1 |
| Diwan, V | 2 |
| Brown, L | 2 |
| Gobe, GC | 2 |
| Ito, S | 1 |
| Ohno, Y | 1 |
| Tanaka, T | 1 |
| Kobuchi, S | 1 |
| Ayajiki, K | 1 |
| Manabe, E | 1 |
| Masuyama, T | 1 |
| Jun-Ichi, S | 1 |
| Tsujino, T | 1 |
| Bond, DA | 1 |
| Alinari, L | 1 |
| Maddocks, K | 1 |
| Kiage, JN | 1 |
| Heimburger, DC | 1 |
| Nyirenda, CK | 1 |
| Wellons, MF | 1 |
| Bagchi, S | 1 |
| Chi, BH | 1 |
| Koethe, JR | 1 |
| Arnett, DK | 1 |
| Kabagambe, EK | 1 |
| Pammi, M | 1 |
| Arumainayagam, J | 1 |
| Kumari, B | 1 |
| Ahmed-Jushuf, I | 1 |
| Carlin, EM | 1 |
| Chandramani, S | 1 |
| Riddell, L | 1 |
| Ghanem, M | 1 |
| Das, S | 1 |
| Wohl, DA | 1 |
| Arnoczy, G | 1 |
| Fichtenbaum, CJ | 1 |
| Campbell, T | 1 |
| Taiwo, B | 1 |
| Hicks, C | 1 |
| McComsey, GA | 1 |
| Koletar, S | 1 |
| Sax, P | 1 |
| Tebas, P | 1 |
| Ha, B | 1 |
| Massengale, K | 1 |
| Walsh, K | 1 |
| Stein, JH | 1 |
| Shaffer, D | 1 |
| Hughes, MD | 1 |
| Sawe, F | 1 |
| Bao, Y | 1 |
| Moses, A | 1 |
| Hogg, E | 1 |
| Lockman, S | 1 |
| Currier, J | 1 |
| Small, D | 1 |
| Kauter, K | 1 |
| Gorriz, JL | 1 |
| Gutiérrez, F | 2 |
| Trullàs, JC | 1 |
| Arazo, P | 1 |
| Arribas, JR | 1 |
| Barril, G | 1 |
| Cervero, M | 1 |
| Cofán, F | 1 |
| Domingo, P | 3 |
| Estrada, V | 1 |
| Fulladosa, X | 1 |
| Galindo, MJ | 1 |
| Gràcia, S | 1 |
| Iribarren, JA | 1 |
| Knobel, H | 2 |
| López-Aldeguer, J | 1 |
| Lozano, F | 1 |
| Martínez-Castelao, A | 1 |
| Martínez, E | 3 |
| Mazuecos, MA | 1 |
| Miralles, C | 2 |
| Montañés, R | 1 |
| Negredo, E | 2 |
| Palacios, R | 2 |
| Pérez-Elías, MJ | 2 |
| Portilla, J | 1 |
| Praga, M | 1 |
| Quereda, C | 1 |
| Rivero, A | 1 |
| Santamaría, JM | 1 |
| Sanz, J | 2 |
| Miró, JM | 1 |
| Huang, BS | 1 |
| Lee, WL | 1 |
| Wang, PH | 1 |
| Wang, ML | 1 |
| Cranford, SW | 1 |
| Michallet, AS | 1 |
| Campidelli, A | 1 |
| Lequeu, H | 1 |
| Dilhuydy, MS | 1 |
| Tournilhac, O | 1 |
| Fornecker, LM | 1 |
| Dupuis, J | 1 |
| Cymbalista, F | 1 |
| De Guibert, S | 1 |
| Delmer, A | 1 |
| Vilque, JP | 1 |
| Ghez, D | 1 |
| Leblond, V | 1 |
| Subtil, F | 1 |
| Feugier, P | 1 |
| Ysebaert, L | 1 |
| Miralles Alvarez, C | 1 |
| Smith, KY | 1 |
| Patel, P | 2 |
| Fine, D | 1 |
| Bellos, N | 1 |
| Sloan, L | 1 |
| Lackey, P | 1 |
| Kumar, PN | 1 |
| Sutherland-Phillips, DH | 1 |
| Vavro, C | 1 |
| Yau, L | 1 |
| Wannamaker, P | 1 |
| Shaefer, MS | 1 |
| Larrousse, M | 1 |
| Podzamczer, D | 3 |
| Pérez, I | 1 |
| Loncá, M | 2 |
| Barragán, P | 2 |
| Deulofeu, R | 1 |
| Casamitjana, R | 1 |
| Mallolas, J | 1 |
| Pich, J | 1 |
| Gatell, JM | 2 |
| Sinn, K | 1 |
| Richardson, R | 1 |
| Carr, A | 1 |
| Goux, A | 1 |
| Feillet-Coudray, C | 1 |
| Jover, B | 1 |
| Fouret, G | 1 |
| Bargnoux, AS | 1 |
| Cassan, C | 1 |
| Richard, S | 1 |
| Badiou, S | 1 |
| Cristol, JP | 1 |
| Choi, AI | 1 |
| Vittinghoff, E | 1 |
| Deeks, SG | 1 |
| Weekley, CC | 1 |
| Shlipak, MG | 1 |
| Soriano, V | 1 |
| Arastéh, K | 1 |
| Migrone, H | 1 |
| Lutz, T | 1 |
| Opravil, M | 1 |
| Andrade-Villanueva, J | 1 |
| Antunes, F | 1 |
| Di Perri, G | 1 |
| Taylor, S | 1 |
| Gellermann, H | 1 |
| de Rossi, L | 1 |
| Saumoy, M | 1 |
| Ordoñez-Llanos, J | 1 |
| Ribera, E | 1 |
| Bonet, R | 1 |
| Curran, A | 1 |
| Rasmussen, TA | 1 |
| Tolstrup, M | 1 |
| Melchjorsen, J | 1 |
| Frederiksen, CA | 1 |
| Nielsen, US | 1 |
| Langdahl, BL | 1 |
| Østergaard, L | 1 |
| Laursen, AL | 1 |
| Kim, C | 1 |
| Gupta, SK | 1 |
| Green, L | 1 |
| Taylor, BM | 1 |
| Deuter-Reinhard, M | 1 |
| Desta, Z | 1 |
| Clauss, M | 1 |
| Bush, T | 1 |
| Overton, T | 1 |
| Baker, J | 1 |
| Hammer, J | 1 |
| Kojic, E | 1 |
| Conley, L | 1 |
| Henry, K | 1 |
| Brooks, JT | 1 |
| Pigossi, SC | 1 |
| Alvim-Pereira, F | 1 |
| Montes, CC | 1 |
| Finoti, LS | 1 |
| Secolin, R | 1 |
| Trevilatto, PC | 1 |
| Scarel-Caminaga, RM | 1 |
| Shobeiri, N | 1 |
| Pang, J | 1 |
| Adams, MA | 1 |
| Holden, RM | 1 |
| KRAUCHER, GK | 1 |
| Nolan, D | 1 |
| Reiss, P | 1 |
| Mallal, S | 1 |
| Maumus, S | 1 |
| Marie, B | 1 |
| Vincent-Viry, M | 1 |
| Siest, G | 1 |
| Visvikis-Siest, S | 1 |
| Llibre, JM | 1 |
| Santos, J | 1 |
| Sánchez-de la Rosa, R | 1 |
| Antela, A | 1 |
| Moreno, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Implanted Loop Recorders (ILR) for the Detection and Management of Arrhythmia in Patients Treated With Bruton Tyrosine Kinase (BTK) Inhibitors[NCT05643235] | 50 participants (Anticipated) | Interventional | 2022-11-01 | Recruiting | |||
| A Randomized, Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma[NCT01578707] | Phase 3 | 391 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Evaluation of Reporting of Cardio-vascular Adverse Events With Antineoplastic and Immunomodulating Agents (EROCA)[NCT03530215] | 500,000 participants (Actual) | Observational | 2018-05-02 | Completed | |||
| A 96-Week, Phase IV, Randomized, Double-Blind, Multicenter Study of the Safety and Efficacy of EPZICOM Versus TRUVADA Administered in Combination With KALETRA in Antiretroviral-Naive HIV-1 Infected Subjects[NCT00244712] | Phase 4 | 688 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1[NCT04904406] | Phase 4 | 95 participants (Anticipated) | Interventional | 2020-10-22 | Recruiting | ||
| Randomized, Open Label Study Evaluating the Lipid Profile Difference and Efficacy of a Combined Therapy Including Tenofovir, Emtricitabine + Atazanavir / r or NVP in Naive HIV - 1 Infected Patients.[NCT00389207] | Phase 3 | 576 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| Efficacy and Safety of Switching From AZT to Tenofovir[NCT00647244] | Phase 4 | 40 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN Study)[NCT00146419] | 699 participants (Actual) | Observational | 2004-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
OS analysis was conducted at the time of study closure, with no adjustment for crossover from the ofatumumab arm to the ibrutinib arm (NCT01578707)
Timeframe: OS analysis was conducted at the time of study closure, including up to 6 years of study follow-up
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 65.1 |
| Ibrutinib (Arm B) | 67.7 |
Overall Response Rate per the IWCLL 2008 criteria as assessed by IRC, limited to the time of primary analysis 06 November 2013 (NCT01578707)
Timeframe: About 18 months after the first subject was enrolled
| Intervention | percentage of participants (Number) |
|---|---|
| Ofatumumab (Arm A) | 4.1 |
| Ibrutinib (Arm B) | 42.6 |
Overall response per the IWCLL 2008 criteria as assessed by Investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | percentage of participants (Number) |
|---|---|
| Ofatumumab (Arm A) | 22.4 |
| Ibrutinib (Arm B) | 87.7 |
The primary objective of this study was to evaluate the efficacy of ibrutinib compared to ofatumumab based on independent review committee (IRC) assessment of progression-free survival (PFS) according to 2008 IWCLL guidelines. (NCT01578707)
Timeframe: Analysis was conducted after observing approximately 117 PFS events, which occurred about 18 months after the first subject was enrolled.
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 8.1 |
| Ibrutinib (Arm B) | NA |
Long-Term Progression Free Survival as assessed by the investigator with up to 6 years of study follow-up (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | months (Median) |
|---|---|
| Ofatumumab (Arm A) | 8.1 |
| Ibrutinib (Arm B) | 44.1 |
Proportion of subjects with hemoglobin (HgB) increase >=20 g/L and platelet (PLT) increase >=50% over baseline continuously for >=56 days without blood transfusions or growth factors. (NCT01578707)
Timeframe: From study initiation to study closure, including up to 6 years of study follow-up
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Hgb Improvement in patient with baseline anemia | Platelet improvement in baseline thrombocytopenia | |
| Ibrutinib (Arm B) | 69.7 | 78.4 |
| Ofatumumab (Arm A) | 32.6 | 9.4 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 48. The percentage of participants with HIV-1 RNA <50 copies/mL were tabulated by treatment arm with stratification by baseline HIV-1 RNA (<100,000 copies/mL and >=100,000 copies/mL). (NCT00244712)
Timeframe: Week 48
| Intervention | percentage of participants (Number) |
|---|---|
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 67.5 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 67.2 |
A blood sample was drawn to determine the CD4+ cell count at Weeks 48 and 96. Change from baseline was defined as CD4+ cell count at week 96 minus CD4+ cell count at baseline. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | cells per cmm (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 201.0 | 250.0 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 173.0 | 246.5 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 48 and 96. Change from baseline was defined as HIV-1 RNA level at Weeks 48 and 96 minus HIV-1 RNA level at baseline. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | log10 copies/mL (Median) | |
|---|---|---|
| Week 48 | Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | -3.142 | -3.114 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | -3.131 | -3.165 |
A blood sample was drawn for participants failing to respond to therapy and the mutations present in the virus were identified. New mutations that developed to the NRTI class at the time of failure that no longer responded to lamivudine or emtricitabine were tabulated by drug class. (NCT00244712)
Timeframe: Baseline and time of virologic failure (up to Week 96)
| Intervention | participants (Number) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance NRTI class (M184V, M/V,M/I,A/V,I,M/I/V) | Reduced pheno susceptibility to lamivudine/M184V | Reduced phen susceptibility to lamivudine/M184M/V | Reduced pheno susceptibility to lamivudine/M184M/I | Reduced pheno susceptibility to lamivudine/M184A/V | Reduced pheno susceptibility to lamivudine/M184I | Reduced pheno suscept. to lamivudine/M184M/I/V | Reduced pheno suscept. to emtricitabine/M184V | Reduced pheno suscept. to emtricitabine/M184M/V | Reduced pheno suscept. to emtricitabine/M184M/I | Reduced pheno suscept. to emtricitabine/M184A/V | Reduced pheno suscept. to emtricitabine/M184I | Reduced pheno suscept. to emtricitabine/M184M/I/V | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 11 | 4 | 3 | 0 | 0 | 0 | 0 | 4 | 3 | 0 | 0 | 0 | 0 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 17 | 9 | 0 | 1 | 1 | 1 | 1 | 9 | 0 | 1 | 1 | 1 | 1 |
A blood sample was drawn for participants failing to respond to therapy and the mutations present in the virus were identified. For each participant, the mutations found at the time of failure were compared with any mutations found in the blood sample at baseline. New mutations that developed at the time of failure was tabulated by drug class. NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor. (NCT00244712)
Timeframe: Baseline and time of virologic failure (up to Week 96)
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| No. with paired genotypes at baseline and wk 96 | Participants with treatment-emergent mutations | NRTI-associated mutations | NNRTI-associated mutations | PI-associated mutations | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 45 | 18 | 11 | 4 | 11 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 41 | 22 | 17 | 3 | 7 |
The number of participants that failed to respond to therapy based on the protocol definition of virologic failure (PDVF) was tabulated. PDVF was defined as either no confirmed HIV-1 RNA <200 copies/mL or HIV-1 RNA rebound >= 200 copies/mL on two consecutive occasions. (NCT00244712)
Timeframe: Baseline to Week 96
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Protocol-defined virologic failure | Fail to confirm HIV-1 RNA <200 copies/mL by wk 24 | Confirmed HIV-1 RNA rebound to >= 200 copies/mL | Suspected HIV-1 RNA rebound to >= 200 copies/mL | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 49 | 21 | 28 | 12 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 48 | 24 | 24 | 11 |
The number of participants that experienced symptoms of a suspected abacavir hypersensitivity reaction was tabulated. The number of participants that developed laboratory signs of proximal renal tubule dysfunction was tabulated. (NCT00244712)
Timeframe: Baseline through 96 weeks
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Participants (Par.) with suspected ABC HSR | Mild or Grade 1 | Moderate or Grade 2 | Severe or Grade 3 | Not Applicable | Par. with proximal renal tubule dysfunction | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 14 | 1 | 8 | 4 | 1 | 0 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 3 | 0 | 2 | 1 | 0 | 5 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 48 and 96. The percentage of participants with HIV-1 RNA <400 copies/mL at Weeks 48 and 96 were tabulated by treatment arm with stratification by baseline HIV-1 RNA levels (<100,000 copies/mL and >=100,000 copies/mL). (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | M/D=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | M/D=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 75.2 | 70.9 | 93.8 | 71.4 | 63.9 | 58.4 | 92.8 | 60.1 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 71.3 | 66.4 | 92.2 | 66.2 | 61.2 | 56.3 | 96.3 | 56.9 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 48 and 96. The percentage of participants with HIV-1 RNA <400 copies/mL at Weeks 48 and 96 were tabulated by treatment arm in participants with baseline HIV-1 RNA <100,000 copies/mL. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | M/D=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | M/D=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 76 | 72 | 94 | 72 | 65 | 60 | 92 | 61 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 71 | 66 | 91 | 65 | 60 | 55 | 97 | 56 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 48 and 96. The percentage of participants with HIV-1 RNA <400 copies/mL at Weeks 48 and 96 were tabulated by treatment arm in participants with baseline HIV-1 RNA >=100,000 copies/mL. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | M/D=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | M/D=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 75 | 70 | 94 | 71 | 63 | 56 | 93 | 59 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 71 | 67 | 94 | 68 | 63 | 58 | 96 | 58 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 48. The percentage of participants with HIV-1 RNA <50 copies/mL at Week 48 were tabulated by treatment arm with stratification by baseline HIV-1 RNA levels (<100,000 copies/mL and >=100,000 copies/mL). (NCT00244712)
Timeframe: Week 48
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| TLOVR | Obs | M/D=F | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 62.6 | 84.3 | 64.3 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 61.1 | 86.8 | 62.3 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 96. The percentage of participants with HIV-1 RNA <50 copies/mL at Week 96 were tabulated by treatment arm with stratification by baseline HIV-1 RNA levels (<100,000 copies/mL and >=100,000 copies/mL). (NCT00244712)
Timeframe: Week 96
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| M=F, Switch Included | TLOVR | Obs | M/D=F | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 59.9 | 52.1 | 86.9 | 56.4 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 58.0 | 51.0 | 91.3 | 54.5 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Weeks 48 and 96. The percentage of participants with HIV-1 RNA <50 copies/mL at Weeks 48 and 96 were tabulated by treatment arm in participants with baseline HIV-1 RNA <100,000 copies/mL. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | MD=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | MD=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 71 | 67 | 89 | 68 | 63 | 57 | 89 | 59 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 69 | 62 | 88 | 62 | 58 | 52 | 94 | 54 |
A blood sample was drawn to determine the amount of HIV-1 RNA virus in copies/mL at Week 48 and 96. The percentage of participants with HIV-1 RNA <50 copies/mL at Weeks 48 and 96 were tabulated by treatment arm in participants with baseline HIV-1 RNA >=100,000 copies/mL. (NCT00244712)
Timeframe: Weeks 48 and 96
| Intervention | percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| M=F, Switch Included, Week 48 | TLOVR, Week 48 | Obs, Week 48 | M/D=F, Week 48 | M=F, Switch Included, Week 96 | TLOVR, Week 96 | Obs, Week 96 | M/D=F, Week 96 | |
| Abacavir/Lamivudine (ABC/3TC) + Lopinavir/Ritonavir (LPV/RTV) | 63 | 57 | 78 | 59 | 56 | 46 | 84 | 54 |
| Tenofovir/Emtricitabine (TDF/FTC) + LPV/RTV | 65 | 60 | 86 | 62 | 58 | 51 | 88 | 55 |
Proportion of Patients reporting CNS (central nervous system) side effects of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 41 |
| Nevirapine BID | 41 |
| Atazanvir/Ritonavir | 37 |
Proportion of Patients reporting hepatic events of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 26 |
| Nevirapine BID | 24 |
| Atazanvir/Ritonavir | 92 |
Proportion of Patients reporting rash of any severity (NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) |
|---|---|
| Nevirapine QD | 75 |
| Nevirapine BID | 64 |
| Atazanvir/Ritonavir | 74 |
Time to loss of virologic response (TLOVR) was defined as the time from start of treatment to the first measurement showing VL ≥ 50 copies/mL in the first virologic rebound, after having a confirmed virological response. (NCT00389207)
Timeframe: Baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 143.86 |
| Nevirapine BID | 143.21 |
| Nevirapine QD+BID | 143.71 |
| Atazanvir/Ritonavir | 143.00 |
Treatment failure is defined as the occurrence of the first of at least one of the following events: early discontinuation of trial drug, change in ARV therapy, failure to achieve an HIV RNA count < 50 copies/mL up to Visit 10 (week 48) or loss of virologic response (NCT00389207)
Timeframe: baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 143.86 |
| Nevirapine BID | 143.21 |
| Nevirapine QD+BID | 143.71 |
| Atazanvir/Ritonavir | 143.00 |
Time to treatment response was defined as the time from start of treatment until the first measurement of the first confirmed virological response (NCT00389207)
Timeframe: baseline to week 144
| Intervention | weeks (Median) |
|---|---|
| Nevirapine QD | 12.00 |
| Nevirapine BID | 12.14 |
| Nevirapine QD+BID | 12.00 |
| Atazanvir/Ritonavir | 23.71 |
Change in CD4+ cell count from baseline among patients on treatment at each visit, with the final visit at Week 144 or EOT (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | cells/mm^3 (Mean) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Change in CD4+ count to Week 4 | Change in CD4+ count to Week 8 | Change in CD4+ count to Week 12 | Change in CD4+ count to Week 24 | Change in CD4+ count to Week 36 | Change in CD4+ count to Week 48 | Change in CD4+ count to Week 60 | Change in CD4+ count to Week 72 | Change in CD4+ count to Week 84 | Change in CD4+ count to Week 96 | Change in CD4+ count to Week 108 | Change in CD4+ count to Week 120 | Change in CD4+ count to Week 132 | Change in CD4+ count to Week 144/EOT | |
| Atazanvir/Ritonavir | 86.1 | 98.0 | 110.9 | 133.8 | 163.4 | 183.6 | 208.2 | 231.9 | 246.4 | 251.6 | 267.2 | 269.2 | 281.3 | 285.8 |
| Nevirapine QD+BID | 77.2 | 105.6 | 120.3 | 134.4 | 160.1 | 168.2 | 184.8 | 213.7 | 223.0 | 217.7 | 231.2 | 231.3 | 243.4 | 251.0 |
Change in the estimated risk of cardiovascular disease using the Framingham algorithm from baseline to after 48, 96 and 144 weeks, last observation carried forward (LOCF). The score is based on age, gender, systolic blood pressure, total cholesterol, high density lipoprotein cholesterol and smoking status. Scores range from 0 to 21 with higher scores indicating a greater risk. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in Framingham score to Week 48 | Change in Framingham score to Week 96 | Change in Framingham score to Week 144/EOT | |
| Atazanvir/Ritonavir | 0.66 | 1.19 | 0.82 |
| Nevirapine QD+BID | 0.50 | 0.93 | 1.14 |
Quality of life (QoL) assessment by change in MHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the Medical Outcomes Study HIV Health Survey (MOS-HIV), a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The MHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in MHS score to Week 48 | Change in MHS score to Week 96 | Change in MHS score to Week 144/EOT | |
| Atazanvir/Ritonavir | 4.52 | 4.89 | 4.70 |
| Nevirapine QD+BID | 6.09 | 6.10 | 4.76 |
QoL assessment by change in PHS score from baseline to after 48, 96 and 144 weeks (observed cases), from the MOS-HIV, a 35-item self-administered questionnaire including 10 scales covering: health perceptions, pain, physical functioning, role functioning, social and cognitive functioning, mental health, energy/fatigue, health distress, and QoL. The PHS is a weighted average of the 10 scales and ranges from 0 to 100 with higher scores indicating better QoL. (NCT00389207)
Timeframe: From baseline to Weeks 48, 96 and 144/EOT
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Change in PHS score to Week 48 | Change in PHS score to Week 96 | Change in PHS score to Week 144/EOT | |
| Atazanvir/Ritonavir | 3.35 | 3.00 | 3.35 |
| Nevirapine QD+BID | 3.34 | 3.19 | 2.22 |
Calculations based on the MDRD algorithm. (NCT00389207)
Timeframe: From baseline to Week 48, 96, 144
| Intervention | mL/min/1.73 m^2 (Mean) | ||
|---|---|---|---|
| change baseline to week 48 (N=143, 128, 271, 173) | change baseline to week 96 (N=130, 122, 252, 157) | change baseline to week 144 (N=163, 168, 331, 174) | |
| Atazanvir/Ritonavir | -7.18 | -11.53 | -9.56 |
| Nevirapine BID | -5.92 | -10.02 | -6.33 |
| Nevirapine QD | -3.91 | -6.93 | -3.27 |
| Nevirapine QD+BID | -4.86 | -8.42 | -4.82 |
Changes frombaseline in total cholesterol, LDL-cholesterol(LDL-c) and HDL (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/dL (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| total cholesterol, week 48 (N=138,122,164) | total cholesterol, week 96 (N=124,114,147) | total cholesterol, week 144 (N=154,155,160) | LDL-c, week 48 (N=136,117,159) | LDL-c, week 96 (N=119,110,145) | LDL-c, week 144 (N=151,150,157) | HDL, week 48(N=138,122,164) | HDL, week 96 (N=124,114,147) | HDL, week 144(N=154,155,160) | |
| Atazanvir/Ritonavir | 20.84 | 29.99 | 28.13 | 10.58 | 19.19 | 17.61 | 3.49 | 4.74 | 5.73 |
| Nevirapine BID | 29.54 | 36.87 | 30.66 | 17.70 | 21.66 | 17.95 | 11.59 | 13.33 | 10.47 |
| Nevirapine QD | 29.28 | 39.17 | 33.12 | 16.54 | 21.93 | 21.42 | 12.06 | 13.86 | 12.61 |
Change of hsCRP from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/L (Mean) | ||
|---|---|---|---|
| hsCRP, week 48 (N=142,126,173) | hsCRP, week 96 (N=128,120,157) | hsCRP, week 144 (N=160,164,174) | |
| Atazanvir/Ritonavir | -0.70 | 0.35 | 0.04 |
| Nevirapine BID | -0.67 | -0.79 | -0.02 |
| Nevirapine QD | -1.01 | -1.54 | -0.09 |
Change of Total cholesterol to HDL-cholesterol ratio from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | ratio (Mean) | ||
|---|---|---|---|
| total triglycerides, week 48 (N=138,122,164) | total triglycerides, week 96 (N=124,114,147) | total triglycerides, week 144 (N=154,155,160) | |
| Atazanvir/Ritonavir | 0.20 | 0.28 | 0.17 |
| Nevirapine BID | -0.33 | -0.25 | -0.07 |
| Nevirapine QD | -0.37 | -0.22 | -0.24 |
Change of total triglycerides from baseline to week 48, 96, 144 (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| total triglycerides, week 48 (N=138,120,164) | total triglycerides, week 96 (N=124,113,147) | total triglycerides, week 144 (N=153,153,159) | |
| Atazanvir/Ritonavir | 36.28 | 30.45 | 27.11 |
| Nevirapine BID | 1.67 | 5.35 | 6.11 |
| Nevirapine QD | 0.08 | 9.34 | -3.46 |
Changes frombaseline apolipoprotein A1 & B (NCT00389207)
Timeframe: baseline to week 48, 96, 144
| Intervention | g/L (Mean) | |||||
|---|---|---|---|---|---|---|
| apolipoprotein A1, week 48 (N=134,121,156) | apolipoprotein A1, week 96 (N=115,106,141) | apolipoprotein A1, week 144 (N=144,140,148) | apolipoprotein B, week 48 (N=134,120,156) | apolipoprotein B, week 96 (N=115,106,141) | apolipoprotein B, week 144 (N=144,139,148) | |
| Atazanvir/Ritonavir | 0.08 | 0.07 | 0.06 | 0.03 | 0.03 | 0.03 |
| Nevirapine BID | 0.23 | 0.23 | 0.14 | 0.03 | -0.00 | 0.05 |
| Nevirapine QD | 0.23 | 0.23 | 0.16 | 0.00 | 0.00 | 0.01 |
Number of treatment-emergent drug-associated substitutions in patients with virological failure up to Week 48. The total number of genotypic mutations in those patients who were virologic failures is given, not the number of patients with mutations. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Number of substitutions (Number) | ||
|---|---|---|---|
| Emtricitabine-associated substitutions at Week 48 | Tenofovir-associated substitutions at Week 48 | Nevirapine-associated substitutions at Week 48 | |
| Atazanvir/Ritonavir | 0 | 0 | 0 |
| Nevirapine QD+BID | 21 | 11 | 34 |
Number of patients with AE elevated serum glucose (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with glycaemic abnormalities | Number without glycaemic abnormalities | |
| Atazanvir/Ritonavir | 3 | 190 |
| Nevirapine QD+BID | 0 | 376 |
Number of patients with AE lipodystrophy (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with lipodystrophy | Number without lipodystrophy | |
| Atazanvir/Ritonavir | 1 | 192 |
| Nevirapine QD+BID | 1 | 375 |
Cost effectiveness assessment by number of patients with non-scheduled physician visits (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
| Intervention | patients (Number) | |||
|---|---|---|---|---|
| Number between baseline and Week 24 | Number between Week 24 and Week 48 | Number between Week 48 and Week 96 | Number between Week 96 and Wk 144/EOT | |
| Atazanvir/Ritonavir | 35 | 35 | 28 | 35 |
| Nevirapine QD+BID | 74 | 45 | 58 | 58 |
Cost effectiveness assessment by number of patients hospitalized (NCT00389207)
Timeframe: From baseline to Week 24, Week 24 to 48, Week 48 to 96, and Week 96 to 144/EOT
| Intervention | Patients (Number) | |||
|---|---|---|---|---|
| Number hospitalized between baseline and Week 24 | Number hospitalized between Week 24 and Week 48 | Number hospitalized between Week 48 and Week 96 | Number hospitalized between Week 96 and Wk 144/EOT | |
| Atazanvir/Ritonavir | 2 | 5 | 5 | 1 |
| Nevirapine QD+BID | 8 | 6 | 5 | 9 |
(NCT00389207)
Timeframe: week 148
| Intervention | participants (Number) | ||
|---|---|---|---|
| DAIDS 2 moderate | DAIDS 3 severe | DAIDS 4 potential lifethreatening | |
| Atazanvir/Ritonavir | 72 | 39 | 9 |
| Nevirapine BID | 84 | 28 | 15 |
| Nevirapine QD | 74 | 30 | 9 |
(NCT00389207)
Timeframe: at Week 48, 96, 144
| Intervention | participants (Number) | ||
|---|---|---|---|
| virologic failure at Week 48 | virologic failure at Week 96 | virologic failure at Week 144 | |
| Atazanvir/Ritonavir | 25 | 13 | 17 |
| Nevirapine BID | 25 | 25 | 28 |
| Nevirapine QD | 20 | 15 | 19 |
| Nevirapine QD+BID | 45 | 40 | 47 |
The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| virologic rebound after CVR at Week 24 | virologic rebound after CVR at Week 48 | virologic rebound after CVR at Week 96 | virologic rebound after CVR at Week 144 | |
| Atazanvir/Ritonavir | 2 | 2 | 2 | 5 |
| Nevirapine BID | 2 | 3 | 6 | 6 |
| Nevirapine QD | 2 | 3 | 3 | 4 |
| Nevirapine QD+BID | 4 | 6 | 9 | 10 |
The analyses of virologic rebound were performed on the original values at each visit(ORGV) rather than calculated results within time windows (CAL) (NCT00389207)
Timeframe: at Week 24, 48, 96, 144
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| virologic rebound after CVR at Week 24 | virologic rebound after CVR at Week 48 | virologic rebound after CVR at Week 96 | virologic rebound after CVR at Week 144 | |
| Atazanvir/Ritonavir | 5 | 12 | 10 | 15 |
| Nevirapine BID | 2 | 5 | 6 | 9 |
| Nevirapine QD | 3 | 4 | 4 | 8 |
| Nevirapine QD+BID | 5 | 9 | 10 | 17 |
VL <400 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | Proportion of patients (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion with VL<400 copies /mL at Week 4 | Proportion with VL<400 copies /mL at Week 8 | Proportion with VL<400 copies /mL at Week 12 | Proportion with VL<400 copies /mL at Week 24 | Proportion with VL<400 copies /mL at Week 36 | Proportion with VL<400 copies /mL at Week 48 | Proportion with VL<400 copies /mL at Week 60 | Proportion with VL<400 copies /mL at Week 72 | Proportion with VL<400 copies /mL at Week 84 | Proportion with VL<400 copies /mL at Week 96 | Proportion with VL<400 copies /mL at Week 108 | Proportion with VL<400 copies /mL at Week 120 | Proportion with VL<400 copies /mL at Week 132 | Proportion with VL<400 copies /mL at Week 144/EOT | |
| Atazanvir/Ritonavir | 0.287 | 0.679 | 0.834 | 0.956 | 0.966 | 0.977 | 0.988 | 0.988 | 0.994 | 0.987 | 1.000 | 0.994 | 0.993 | 0.986 |
| Nevirapine QD+BID | 0.365 | 0.714 | 0.856 | 0.924 | 0.968 | 0.985 | 0.993 | 0.996 | 0.988 | 1.000 | 0.996 | 1.000 | 0.996 | 0.991 |
VL <50 copies/mL among observed patients on treatment at each visit, with the final visit at Week 144 or end of trial (EOT) for the patient (NCT00389207)
Timeframe: From baseline to Weeks 4, 8, 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144/EOT
| Intervention | Proportion of patients (Number) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proportion with VL<50 copies /mL at Week 4 | Proportion with VL<50 copies /mL at Week 8 | Proportion with VL<50 copies /mL at Week 12 | Proportion with VL<50 copies /mL at Week 24 | Proportion with VL<50 copies /mL at Week 36 | Proportion with VL<50 copies /mL at Week 48 | Proportion with VL<50 copies /mL at Week 60 | Proportion with VL<50 copies /mL at Week 72 | Proportion with VL<50 copies /mL at Week 84 | Proportion with VL<50 copies /mL at Week 96 | Proportion with VL<50 copies /mL at Week 108 | Proportion with VL<50 copies /mL at Week 120 | Proportion with VL<50 copies /mL at Week 132 | Proportion with VL<50 copies /mL at Week 144/EOT | |
| Atazanvir/Ritonavir | 0.09 | 0.25 | 0.412 | 0.779 | 0.83 | 0.886 | 0.901 | 0.915 | 0.896 | 0.924 | 0.968 | 0.955 | 0.947 | 0.929 |
| Nevirapine QD+BID | 0.107 | 0.304 | 0.515 | 0.842 | 0.907 | 0.931 | 0.959 | 0.965 | 0.972 | 0.98 | 0.964 | 0.976 | 0.971 | 0.952 |
Number of patients with AE elevated serum lipids (i.e. hypercholesterolaemia) (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | patients (Number) | |
|---|---|---|
| Number with serum lipid abnormalities | Number without serum lipid abnormalities | |
| Atazanvir/Ritonavir | 4 | 189 |
| Nevirapine QD+BID | 9 | 367 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 144 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 144. (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | participants (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 143 | 50 |
| Nevirapine BID | 113 | 75 |
| Nevirapine QD | 121 | 67 |
| Nevirapine QD+BID | 234 | 142 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 48 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 48. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Patients (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 126 | 67 |
| Nevirapine BID | 124 | 64 |
| Nevirapine QD | 126 | 62 |
| Nevirapine QD+BID | 250 | 126 |
Treatment response is defined as a VL <50 copies/mL measured at two consecutive visits up to Week 48 and without subsequent rebound or change of ARV therapy up to Week 48, based on time to loss of virologic response (TLOVR) algorithm, as a sensitivity analysis for the primary analysis. (NCT00389207)
Timeframe: From baseline to Week 48
| Intervention | Patients (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 142 | 51 |
| Nevirapine QD+BID | 261 | 115 |
Treatment response is defined as a viral load (VL) <50 copies/mL measured at two consecutive visits prior to Week 96 and without subsequent rebound or change of antiretroviral (ARV) therapy prior to Week 96. (NCT00389207)
Timeframe: From baseline to Week 96
| Intervention | participants (Number) | |
|---|---|---|
| Number of responders | Number of non-responders | |
| Atazanvir/Ritonavir | 149 | 44 |
| Nevirapine BID | 122 | 66 |
| Nevirapine QD | 131 | 57 |
| Nevirapine QD+BID | 253 | 123 |
Treatment-emergent AIDS-defining illness (tr.-emerg. AIDS-def.illness) including worsening during treatment (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with tr.-emerg. AIDS-def.illness | Number without tr.-emerg. AIDS-def.illness | |
| Atazanvir/Ritonavir | 7 | 186 |
| Nevirapine QD+BID | 26 | 350 |
Patients with an AIDS-defining illness leading to death broken out by treatment. Statistical analysis shows time to death from AIDS-defining illness. (NCT00389207)
Timeframe: From baseline to Week 144
| Intervention | Patients (Number) | |
|---|---|---|
| Number with AIDS-def. illness leading to death | Number without AIDS-def. illness leading to death | |
| Atazanvir/Ritonavir | 0 | 193 |
| Nevirapine QD+BID | 3 | 373 |
6 reviews available for adenine and Cardiovascular Diseases
| Article | Year |
|---|---|
Programmable Genome-Editing Technologies as Single-Course Therapeutics for Atherosclerotic Cardiovascular Disease.
Topics: Adenine; Animals; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; CRISPR-Cas Systems; Ge | 2022 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Adenine-induced chronic kidney disease in rats.
Topics: Adenine; Animals; Bone Diseases; Cardiovascular Diseases; Disease Models, Animal; Disease Progressio | 2018 |
Bruton tyrosine kinase inhibitors for the treatment of mantle cell lymphoma: review of current evidence and future directions.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antigens, CD20; Antineoplastic Agents; Antineoplastic | 2019 |
[Are all analogue combinations equal?].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Dis | 2008 |
Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardi | 2005 |
9 trials available for adenine and Cardiovascular Diseases
| Article | Year |
|---|---|
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, I | 2019 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Topics: A549 Cells; Acetylmuramyl-Alanyl-Isoglutamine; Acinetobacter baumannii; Acute Lung Injury; Adaptor P | 2016 |
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Cardio | 2021 |
Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE).
Topics: Adenine; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; | 2014 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 | 2009 |
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosi | 2010 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtrici | 2011 |
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Deox | 2011 |
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cardiovascular D | 2011 |
25 other studies available for adenine and Cardiovascular Diseases
| Article | Year |
|---|---|
Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
Topics: Adenine; Aged; Aged, 80 and over; Canada; Cardiovascular Diseases; Case-Control Studies; Cohort Stud | 2021 |
Weight changes in patients with sustained viral suppression switching tenofovir disoproxil fumarate to tenofovir alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol; Drug Substitution; F | 2022 |
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
Topics: Adenine; Atrial Fibrillation; Cardiovascular Diseases; Humans; Piperidines; Pyrazoles; Pyrimidines; | 2020 |
Cardiovascular Toxicities Associated With Ibrutinib.
Topics: Adenine; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cardiovascular Diseases; | 2019 |
Real-Life Insight Into Ibrutinib Cardiovascular Events: Defining the Loose Ends.
Topics: Adenine; Cardiovascular Diseases; Humans; Piperidines; Pyrazoles; Pyrimidines | 2019 |
Factors Associated with Mutations: Their Matching Rates to Cardiovascular and Neurological Diseases.
Topics: Adenine; Cardiovascular Diseases; Genetic Predisposition to Disease; Humans; Mutation; Nervous Syste | 2021 |
Neutrophil/lymphocyte ratio elevation in renal dysfunction is caused by distortion of leukocyte hematopoiesis in bone marrow.
Topics: Adenine; Aged; Aged, 80 and over; Animals; Biomarkers; Bone Marrow; Carbon; Cardiovascular Diseases; | 2019 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxa | 2013 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cycl | 2013 |
Comparison of cardiovascular disease risk markers in HIV-infected patients receiving abacavir and tenofovir: the nucleoside inflammation, coagulation and endothelial function (NICE) study.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Blood Coagulation; Cardiovascular Diseases; Dideoxynucl | 2014 |
Gender differences in adenine-induced chronic kidney disease and cardiovascular complications in rats.
Topics: Adenine; Animals; Blood Pressure; Cardiovascular Diseases; Estrogens; Female; In Vitro Techniques; K | 2014 |
[Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients].
Topics: Adenine; Algorithms; Anti-HIV Agents; Biopsy; Cardiovascular Diseases; Disease Management; Evidence- | 2014 |
The slowing down of renal deterioration but acceleration of cardiac hypertrophy: is the estrogen receptor-α a hero or villain?
Topics: Adenine; Animals; Cardiovascular Diseases; Female; Male; Renal Insufficiency, Chronic | 2014 |
Ranking of Molecular Biomarker Interaction with Targeted DNA Nucleobases via Full Atomistic Molecular Dynamics.
Topics: Acetone; Adenine; Biomarkers; Biosensing Techniques; Cardiovascular Diseases; Cytosine; Diabetes Mel | 2016 |
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Dose-Response Rela | 2017 |
Lower arterial stiffness and Framingham score after switching abacavir to tenofovir in men at high cardiovascular risk.
Topics: Adenine; Cardiovascular Diseases; Dideoxynucleosides; HIV Infections; Humans; Male; Middle Aged; Org | 2010 |
NADPH oxidase activity is associated with cardiac osteopontin and pro-collagen type I expression in uremia.
Topics: Adenine; Animals; Blotting, Western; Cardiovascular Diseases; Catalase; Collagen Type I; Diet, Prote | 2011 |
Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.
Topics: Adenine; Anti-Retroviral Agents; Biomarkers, Pharmacological; Cardiovascular Diseases; CD4 Lymphocyt | 2011 |
Abacavir, didanosine and tenofovir do not induce inflammatory, apoptotic or oxidative stress genes in coronary endothelial cells.
Topics: Adenine; Anti-HIV Agents; Apoptosis; Cardiovascular Diseases; Cell Adhesion Molecules; Coronary Vess | 2011 |
Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Case-Control Studies; Dideoxyn | 2012 |
Genetic association study between Interleukin 10 gene and dental implant loss.
Topics: Adenine; Alleles; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular | 2012 |
Cardiovascular disease in an adenine-induced model of chronic kidney disease: the temporal link between vascular calcification and haemodynamic consequences.
Topics: Adenine; Animals; Blood Pressure; Cardiovascular Diseases; Disease Models, Animal; Hemodynamics; Mal | 2013 |
[Treatment of circulatory disorders with adenine compounds].
Topics: Adenine; Cardiovascular Diseases; Humans | 1955 |
Analysis of the effect of multiple genetic variants of cardiovascular disease risk on insulin concentration variability in healthy adults of the STANISLAS cohort. The role of FGB-455 G/A polymorphism.
Topics: Adenine; Adult; Cardiovascular Diseases; Cohort Studies; Cross-Sectional Studies; Fasting; Female; F | 2007 |
Sustained improvement of dyslipidaemia in HAART-treated patients replacing stavudine with tenofovir.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Disease | 2006 |